NEW YORK (GenomeWeb News) – Theradiag said today that it has received the CE Mark for two new biotherapy monitoring kits: tocilizumab and rituximab. Tocilizumab is an immunosuppressive drug used to treat rheumatoid arthritis and juvenile idiopathic arthritis, while rituximab is prescribed for treatment of leukemia and lymphoma. The Theradiag kits are sold under the Lisa Tracker brand name.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.